Compare Ginkgo Bioworks Holdings Inc (DNA) vs iShares Core MSCI EAFE ETF (IEFA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs iShares Core MSCI EAFE ETF — how do they compare? Ginkgo Bioworks Holdings Inc trades at $13 (market cap $763.64M), while iShares Core MSCI EAFE ETF trades at $96.52 (market cap $189.19B). The key difference: iShares Core MSCI EAFE ETF is far larger — about 247.7× Ginkgo Bioworks Holdings Inc's market cap, and iShares Core MSCI EAFE ETF is more actively traded (8,441,787 versus 3,204,177). Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and iShares Core MSCI EAFE ETF for 40 Days on average.
| DNA | IEFA | |
|---|---|---|
Market Cap | $763.64M | $189.19B |
Volume | 3,204,177 | 8,441,787 |
Sector | Health | Broad Market / Factor |
52-Week High | $15.83 | $101.41 |
52-Week Low | $5.48 | $85.06 |
Typical Hold Time | 7 Days | 40 Days |
Enterprise Value | $865.59M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $13.00, up 13.34% today, with a bullish technical signal from moving averages. The company shows strong gross margins of 68.04% but remains unprofitable with a -219.6% net margin. Recent news includes a $17.5M ARPA-H subcontract for RNA medicine manufacturing and partnership expansions, though revenue declined to $132M in 2026.
DNA presents high risk with significant losses and cash burn, but analyst sentiment is divided with equal buy/sell ratings. Investment appeal hinges on future profitability from recent partnerships and government contracts, while current financials and negative cash flow pose substantial downside risk.
IEFA, the iShares Core MSCI EAFE ETF, trades at $96.52, up 0.33% on the day, but technical indicators signal a bearish trend with moving averages and oscillators in sell territory. The ETF provides exposure to developed markets outside North America, holding $196 billion in assets under management and offering a competitive expense ratio of 0.07%. Recent financial news highlights its role in international diversification, comparing favorably to peers on dividend yield and cost efficiency.
The outlook for IEFA is tempered by near-term technical weakness and broader market shifts away from concentrated U.S. tech exposure. Key risks include geopolitical tensions and interest rate uncertainty, but its low-cost structure and focus on established economies provide a defensive tilt for long-term investors seeking international diversification amid S&P 500 concentration concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About iShares Core MSCI EAFE ETF
IEFA tracks the MSCI EAFE Investable Market Index, offering broad exposure to large, mid, and small-cap stocks in developed markets across Europe, Australasia, and the Far East. It serves as a low-cost core holding for international diversification, excluding the U.S. and Canada.
Read more on IEFA →
